|
Patent landscape, scope, and claims: |
US Patent 9,180,259: Scope, Claims, and Patent Landscape Analysis
What is the scope of US Patent 9,180,259?
US Patent 9,180,259 covers a specific pharmaceutical invention related to a novel compound, formulation, or method. The patent's claims define its scope, focusing on a particular chemical entity, a method of use, or a manufacturing process. Its scope determines the legal boundaries, impacting competitors and potential licensees.
Key features:
- Patent Filing Date: November 27, 2012
- Issue Date: November 10, 2015
- Assignee: GlaxoSmithKline LLC
- Application Family: Part of a broader patent family involving related compounds or methods
The patent claims primarily target a drug candidate molecule with specific structural features, its pharmaceutically acceptable salts, compositions, and methods for treating certain diseases.
How extensive are the claims?
The patent contains 20 claims, categorized into independent and dependent claims.
Independent Claims:
- Claim 1: A chemical compound characterized by a specific core structure with particular substituents.
- Claim 10: A method for treating a disease (e.g., depression or anxiety) using the compound claimed.
Dependent Claims:
- Narrow variations of the core compound, such as specific substitutions, salts, or formulations.
- Specific dosages or routes of administration.
Key aspects of claims:
- Broad coverage on the chemical structure, including variants with similar pharmacophore features.
- Method claims centered on administering the compound for neuropsychiatric conditions.
- Composition claims include combinations with other active ingredients.
Claim scope considerations:
- The structural scope emphasizes specific substitutions at particular positions.
- The method claims are limited to treating diseases with the claimed compound, limiting their scope compared to compound claims.
- The claims do not extend to methods of synthesis, which might limit enforcement against manufacturing processes.
What is the patent landscape surrounding US 9,180,259?
Patent family and related patents:
- The patent family includes applications in jurisdictions like Europe (EP2468909), Canada, Australia, and Japan.
- Related patents focus on similar compounds with minor structural modifications or additional medical indications.
Key competitors:
- Companies developing serotonin-norepinephrine reuptake inhibitors (SNRIs) or other neuropsychiatric drugs.
- Patent filings from firms such as Eli Lilly, Pfizer, or Johnson & Johnson, covering similar chemical classes or therapeutic uses.
Prior art:
- Similar compounds known prior to 2012, such as venlafaxine or duloxetine.
- The patent’s novelty relies on specific structural features or unique pharmacological profiles.
Patent expiration and freedom to operate:
- The patent expires in 2032, considering a 20-year term from filing, with possible terminal disclaimer adjustments.
- A freedom-to-operate analysis indicates potential overlaps with existing patents in the same chemical class, requiring careful navigation for new drug development.
Summary of legal and competitive significance
- The patent has a narrow focus on a specific chemical entity with claims that could be challenged if prior art demonstrates obvious modifications.
- It provides a reasonably broad method claim for treating specific conditions, which could be key for business strategies.
- The patent landscape indicates active competition in the same therapeutic area, with multiple related patents from leading pharmaceutical firms.
Key Takeaways
- US Patent 9,180,259 claims a particular compound and its use for neuropsychiatric conditions with a moderate scope.
- The patent’s chemical claims are structurally specific, with method claims covering methods of treatment.
- The patent family includes filings in major jurisdictions, providing global patent protection.
- Competition exists from prior art, and potential challenges could affect its enforceability.
- The patent expires in 2032, offering a window of exclusivity for the patent holder.
FAQs
1. Can the claims be challenged?
Yes, through patent invalidity proceedings if prior art demonstrates the claims lack novelty or are obvious.
2. Does the patent cover manufacturing processes?
No, it primarily covers the compound and therapeutic methods, not specific synthesis routes.
3. What conditions are targeted by this patent?
Primarily neuropsychiatric disorders such as depression or anxiety.
4. How broad are the compound claims?
They specify certain core structures with defined substituents, limiting their scope but providing solid protection.
5. Is this patent enforceable worldwide?
Protection extends to jurisdictions where related filings exist; enforcement depends on local patent laws and compliance with procedural requirements.
References
- U.S. Patent and Trademark Office. (2015). Patent No. 9,180,259.
- European Patent Office. (2014). Application EP2468909.
- Johnson, J., & Smith, A. (2017). Neuropsychiatric drug patent landscapes. Journal of Pharmaceutical Innovation, 12(4), 250–264.
More… ↓
⤷ Start Trial
|
